Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Subscribe To Our Newsletter & Stay Updated
